@article{TGH5546,
author = {Marieke J. H. Coenen},
title = {NUDT15 genotyping in Caucasian patients can help to optimise thiopurine treatment in patients with inflammatory bowel disease},
journal = {Translational Gastroenterology and Hepatology},
volume = {4},
number = {0},
year = {2019},
keywords = {},
abstract = {Thiopurines [azathioprine (AZA) and 6-mercaptopurine (6- MP)] are frequently used for the treatment of inflammatory bowel disease (IBD). Unfortunately ~10–30% of the patients develop adverse drug reactions (1). Myelosuppression is one of the thiopurine related side-effects observed in ~5% of IBD patients from European descent (2-4). The course of thiopurine-induced myelosuppression is relatively mild but patients with this side-effect are more prone to serious infections. It is known that genetics can explain part of the thiopurine-induced myelosuppression.},
issn = {2415-1289}, url = {https://tgh.amegroups.org/article/view/5546}
}